GO
Loading...

Enter multiple symbols separated by commas

Stocks Biogen Inc

More

  • NEW YORK— Swiss drugmaker Novartis is buying a potential once-a-month multiple sclerosis drug from GlaxoSmithKline and could pay more than $1 billion in the latest deal between the two companies. Novartis currently sells the drug as a treatment for a type of leukemia, the result of a larger deal with GlaxoSmithKline. Novartis aims to start a late-stage...

  • Cramer: Why Apple is not for the squeamish Tuesday, 4 Aug 2015 | 6:12 PM ET
    Customers pose for a photograph inside Apple Inc.'s new Canton Road store in the Tsim Sha Tsui district of Hong Kong, China, on Thursday, July 30, 2015.

    Jim Cramer saw that investors could not hide from big bad China on Tuesday, including Apple.

  • Aug 4- The U.S. Food and Drug Administration said it will update the label of Novartis AG's multiple sclerosis drug, Gilenya, after cases of serious brain infections were linked with its use. As a result, information about these cases is being added to the oral drug's label, the FDA said. The FDA had said in August 2013 that it was investigating a case of PML in a patient...

  • We're 'losing' Apple: Technician Tuesday, 4 Aug 2015 | 11:10 AM ET
    A pedestrian passes an Apple store in San Francisco.

    Carter Worth says the recent price action in Apple could spell trouble for the Nasdaq.

  • Markets oversold, but these leaders still holding up Tuesday, 28 Jul 2015 | 10:14 AM ET
    Traders work on the floor of the New York Stock Exchange.

    There is a lot of money hiding out in a few sub-groups, including banks, biotech, and Internet names like Google and Facebook.

  • NEW YORK, July 27- Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger. As head of Actavis, he then sealed a $66 billion purchase of Botox-maker Allergan, beating out rival suitor Valeant...

  • NEW YORK, July 27- Allergan CEO Brent Saunders said on Monday the company will use the $36 billion it nets from the sale of its generics business to Teva for more deals, including large, "transformational" merger opportunities. Saunders, who led the $66 billion combination of Actavis and Allergan that closed only a few months ago, told investors that it would use the...

  • Cramer Remix: This stock has lost its mojo Friday, 24 Jul 2015 | 6:56 PM ET
    Jim Cramer on Mad Money.

    “Mad Money” host Jim Cramer says he’s being kind with his criticism of this popular ratings and reviews company.

  • Cramer: Not enough leadership for a comeback Friday, 24 Jul 2015 | 6:31 PM ET
    Pedestrians walk past a Capital One ATM outside of a bank branch in New York.

    Jim Cramer thinks leadership is lacking, which prompted the market to get crushed Friday.

  • Pisani: What's worrying traders about Q3 earnings Friday, 24 Jul 2015 | 4:13 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Dollar strength, weak oil weigh on earnings.

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed about 1 percent lower, despite surprisingly strong Amazon earnings, as signs of slower global growth weighed on sentiment.

  • Here’s what’s weighing down this biotech stock Friday, 24 Jul 2015 | 1:57 PM ET
    A worker in a Biogen lab.

    Biogen shares sank after it lowered its 2015 forecast on slower-than-anticipated growth of its multiple sclerosis blockbuster Tecfidera.

  • *Tecfidera U.S. growth to be flat for rest of 2015. July 24- Biogen Inc more than halved its sales growth forecast for 2015, saying it expects demand for its flagship multiple sclerosis drug, Tecfidera, to continue slowing this year in the United States. Biogen's stock fell as much as 18.8 percent to a seven-month low, wiping out about $17 billion of its value, after the...

  • Rough morning for this biotech stock Friday, 24 Jul 2015 | 10:43 AM ET
    Rough morning for this biotech stock

    CNBC's Meg Tirrell reports on Biogen's sales growth as the company misses sales estimates.

  • Cramer's Mad Dash: Biogen's biotech blues Friday, 24 Jul 2015 | 9:24 AM ET
    Cramer's Mad Dash: Biogen's biotech blues

    Jim Cramer explains why he is watching shares of Biogen after the company lowered its guidance

  • Futures narrowly mixed despite Amazon beat Friday, 24 Jul 2015 | 9:19 AM ET
    American Airlines

    U.S. stock futures pointed to a slight rebound following a stronger-than-expected earnings report from online retailer Amazon.

  • Early movers: CI, AMZN, SAVE, BIIB, MCO, T & more Friday, 24 Jul 2015 | 7:54 AM ET

    Some of the names on the move ahead of the open.

  • July 24- Sales of Biogen Inc's roster of multiple sclerosis drugs failed to meet analysts' expectation, prompting the company to slash its full-year profit and sales forecast. Tecfidera's sales were $833 million in the second quarter ended June 30, well below Wall Street's estimate of about $933 million, according to Evercore ISI. Sales of Biogen's injectable...

  • Biogen profit rises 30 pct on higher Tecfidera sales Friday, 24 Jul 2015 | 6:59 AM ET

    July 24- Biogen Inc reported a 30 percent rise in quarterly profit, driven by strong sales of its top-selling oral multiple sclerosis drug, Tecfidera. Net profit attributable to Biogen rose to $927.3 million, or $3.93 per share, in the second quarter ended June 30, from $714.5 million, or $3.01 per share, a year earlier. The U.S. biotechnology company's revenue rose...

  • US stocks set for rebound as Amazon shares surge Friday, 24 Jul 2015 | 6:06 AM ET

    U.S. stock futures pointed to a rebound for Wall Street shares Friday, following a stronger-than-expected earnings report from online retailer Amazon.